Cellular Therapy Tracking Market Report 2026

The cellular therapy tracking market size has grown rapidly in recent years. It will grow from $2.9 billion in 2025 to $3.28 billion in 2026 at a compound annual growth rate (CAGR) of 13.1%. The growth in the historic period can be attributed to increasing clinical trial activity for cell therapies, rising regulatory scrutiny on advanced therapies, growth in personalized medicine programs, early adoption of digital tracking systems, expansion of biologics manufacturing.

The cellular therapy tracking market size is expected to see rapid growth in the next few years. It will grow to $5.31 billion in 2030 at a compound annual growth rate (CAGR) of 12.8%. The growth in the forecast period can be attributed to increasing commercialization of cell and gene therapies, rising demand for real-time therapy visibility, expansion of decentralized clinical trials, growing focus on patient safety and compliance, increased investment in digital health infrastructure. Major trends in the forecast period include increasing adoption of end-to-end therapy traceability platforms, growing integration of compliance and reporting software, rising use of real-time supply chain monitoring, expansion of data-driven workflow optimization tools, enhanced focus on regulatory transparency.

The growing adoption of personalized medicine is expected to drive the cellular therapy tracking market in the coming years. Personalized medicine tailors treatment and prevention strategies to an individual’s genetic makeup, lifestyle, and environment. This approach is increasingly adopted due to advances in genomics, which enable precise identification of genetic variations and individualized therapies. Cellular therapy tracking supports personalized medicine by ensuring accurate monitoring and management of patient-specific cells throughout the therapy process. It enhances treatment safety and effectiveness by providing end-to-end traceability, regulatory compliance, and streamlined workflows for healthcare providers. For example, in February 2024, the Personalized Medicine Coalition (PMC), a US-based nonprofit organization, reported that the FDA approved 26 new personalized medicines in 2023, a notable increase from 12 approvals in 2022. This rising adoption of personalized medicine is therefore fueling the growth of the cellular therapy tracking market.

Key companies in the cellular therapy tracking market are focusing on developing scalable platforms, such as chain of identity (COI) management systems, to ensure cell traceability, regulatory compliance, and patient safety. COI management platforms are digital solutions that track and verify the identity of patient-specific cells throughout the therapy process, maintaining full traceability and safety. For instance, in May 2023, TrakCel Limited, a UK-based software company, launched OCELLOS Core, a COI management platform within its OCELLOS suite, designed for early-stage autologous and personalized cell and gene therapy (CGT) clinical trials. The platform provides automated COI tracking, ensuring accurate patient records from the first enrollment. Its pre-configured, validated system can be deployed within 2-3 weeks and offers scalable, cost-effective solutions as therapies progress from trials to commercialization. The system also tracks chain-of-custody events with complete audit trails, enhancing compliance and collaboration.

In June 2025, STEMCELL Technologies Inc., a Canada-based biotechnology company, acquired Cellular Highways Ltd. for an undisclosed amount. Through this acquisition, STEMCELL Technologies aims to integrate Cellular Highways’ advanced cell sorting technology into its portfolio, improving the efficiency, scalability, and precision of cellular therapy manufacturing and tracking. Cellular Highways Ltd., based in the UK, specializes in advanced cell sorting technologies for cellular therapy tracking.

Major companies operating in the cellular therapy tracking market are Johnson & Johnson, Novartis AG, Bristol-Myers Squibb Company, Thermo Fisher Scientific Inc., Gilead Sciences Inc., Merck KGaA, GE Healthcare Technologies Inc., Becton Dickinson and Company, Lonza Group Ltd., Nikon Corporation, Charles River Laboratories International Inc., Sartorius AG, Bio-Rad Laboratories Inc., Bio-Techne Corporation, Miltenyi Biotec B.V. & Co. KG, Promega Corporation, Vericel Corporation, Adaptimmune Therapeutics plc, Medipost Co. Ltd., TrakCel.

North America was the largest region in the cellular therapy tracking market in 2025. The regions covered in the cellular therapy tracking market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the cellular therapy tracking market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the cellular therapy tracking market by increasing costs of imported IT hardware, data security systems, cloud infrastructure components, and specialized software platforms used in therapy lifecycle management. Biotechnology companies and hospitals in North America and Europe are most affected due to reliance on imported digital infrastructure, while Asia-Pacific faces higher implementation costs for enterprise systems. These tariffs are raising deployment expenses and slowing digital transformation initiatives. However, they are also encouraging regional software development, localized cloud infrastructure investment, and domestic innovation in therapy tracking solutions.

The cellular therapy tracking market research report is one of a series of new reports that provides cellular therapy tracking market statistics, including cellular therapy tracking industry global market size, regional shares, competitors with a cellular therapy tracking market share, detailed cellular therapy tracking market segments, market trends and opportunities, and any further data you may need to thrive in the cellular therapy tracking industry. This cellular therapy tracking market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Cellular therapy tracking is the systematic process of monitoring and managing the entire lifecycle of cellular therapies, from cell collection and manufacturing to distribution, administration, and long-term patient outcomes. It ensures product integrity, regulatory compliance, patient safety, and treatment effectiveness through comprehensive data capture and traceability. Additionally, it helps optimize workflow efficiency and maintain accurate documentation throughout the therapy process.

The main product types for cellular therapy tracking include software and services. The software consists of digital platforms and tools designed to manage, monitor, and organize data related to cell therapy operations and processes. It finds applications in areas such as cancer, cardiovascular diseases, musculoskeletal disorders, and more, serving end users including hospitals, research institutes, biotechnology companies, and other relevant organizations.

The cellular therapy tracking market includes revenues earned by entities through logistics management, temperature-controlled shipping, chain of custody compliance, consulting and advisory support, cryopreservation, secure biostorage, end-to-end supply chain solutions, and quality assurance support. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.